Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis.

ABSTRACT:

Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and immunosuppressive therapy (IST) are two major competing treatment strategies for acquired aplastic anemia (AA). Whether allo-HSCT is superior to IST as a front-line treatment for patients with AA has been a subject of debate. To compare the efficacy and safety of allo-HSCT with that of IST as a front-line treatment for patients with AA, we performed a meta-analysis of available studies that examined the impact of the two major competing treatment strategies for AA.

Results

Fifteen studies including a total of 5336 patients were included in the meta-analysis. The pooled hazard ratio (HR) for overall survival (OS) was 0.4 (95% CI 0.074-0.733, P = 0.016, I² = 58.8%) and the pooled HR for fa

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC7059290 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature